AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits and consistent safety data.

AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE® (mirvetuximab soravtansine-gynx) in women with folate ...

Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. Elahere has interactions with some other drugs. Examples include certain ...

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

AbbVie’s Elahere (mirvetuximab soravtansine-gynx) has demonstrated consistent survival benefits in a subset of ovarian cancer ...

AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE� (mirvetuximab soravtansine-gynx) in women with folate ...

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα ...

Elahere showed superior efficacy over chemotherapy in progression-free survival, objective response rate, and overall survival in the MIRASOL trial. The treatment reduced the risk of tumor progression ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...